Rosemont to buy Aytu in roughly $56m cash deal
Aytu has agreed to a $2.70-a-share offer from Rosemont Pharmaceuticals Holdings, announced with quarterly results showing a sales rise and a persistent net loss.
Rosemont Pharmaceuticals Holdings has agreed to acquire Aytu BioPharma for $2.70 per share in cash, a deal the companies value at about $56m. The transaction is structured as a tender offer, in which the buyer makes its offer directly to shareholders. Closing is expected by the end of 2026.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Aytu Biopharma, Inc ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.